Contrary to expectations, imatinib showed minimal tumor suppression (about 1% inhibition rate, p = 0.8844), while KIT-d-MMAE significantly inhibited tumor growth (about 70% inhibition rate, p < 0.0001), outperforming both imatinib and VcMMAE (Figure 7E-G). This evidence concerns the gene KIT and neoplasm.